Archives
-
Irinotecan in Translational DNA-Damage Research
2026-09-10
Irinotecan (CPT-11) is more than a colorectal cancer cytotoxicity tool: it is a schedule-sensitive probe of topoisomerase I–mediated DNA damage. This article connects its SN-38 activation biology with practical assay design and carefully interprets lessons from topotecan research without treating the two agents as interchangeable.
-
ICOS Signaling and Th2 Differentiation in Allergic Rhinitis
2026-09-10
This study identifies ICOS-expressing Th2 cells as a clinically relevant component of allergic rhinitis, linking their abundance to symptom severity and changes during subcutaneous immunotherapy. Its combination of peripheral-blood immunophenotyping, longitudinal follow-up, and pathway perturbation supports the PI3K-Akt-mTOR axis as a mechanistic connection between ICOS signaling and Th2 differentiation.
-
Triiodothyronine (T3): Mechanism and Workflows
2026-09-09
Triiodothyronine (T3) is the receptor-active thyroid hormone used to study gene regulation, metabolism, and endocrine signaling in controlled models. This article connects product specifications with receptor biology, assay design, handling, and experimental limits.
-
Deferasirox Fe3+ chelate: Assay Guide
2026-09-09
A scenario-based guide to using Deferasirox Fe3+ chelate (SKU A3355) in iron-sensitive viability, proliferation, and cytotoxicity workflows. It connects formulation control with recent evidence on mitochondrial ROS, NF-kB signaling, and myeloid differentiation while distinguishing validated product data from practical assay recommendations.
-
Dacomitinib (PF-00299804) Lab Workflows
2026-09-08
A scenario-based guide to using Dacomitinib (PF-00299804), SKU A8319, in cell viability, proliferation, cytotoxicity, and signaling studies. It connects pan-HER pharmacology with practical stock preparation, assay controls, resistance models, and carefully bounded ferroptosis research applications.
-
IPA Feedback Control in Auxin Biosynthesis
2026-09-08
The 2022 PNAS study identifies indole-3-pyruvic acid (IPyA, also commonly called IPA) as a negative-feedback regulator of TAA1/TAR aminotransferases in the two-step auxin pathway. Its kinetic and cross-species evidence explains how plants balance IPyA production and consumption to limit inappropriate indole-3-acetic acid formation.
-
How Inhibitors Accelerate p38α Dephosphorylation
2026-09-07
The reference study shows that some kinase inhibitors do more than block p38α catalytic activity: they reshape the activation loop so WIP1 can remove its activating phosphate more efficiently. This dual-action mechanism provides a structural framework for designing inhibitors that suppress signaling both immediately and through accelerated pathway shutoff.
-
Protecting Mechanistic Truth in Cancer Protein Studies
2026-09-07
A translational framework for connecting protease control with mechanistic cancer biology, using the ciclopirox–bioenergetics–ER stress axis as a case study and positioning an EDTA-free cocktail for more reliable protein workflows.
-
Protease Inhibitor Cocktail in Alzheimer’s Assays
2026-09-05
Discover how a Protease Inhibitor Cocktail can preserve TALDO1-centered metabolic evidence in Alzheimer’s disease research. This guide connects EDTA-free inhibitor chemistry with Western blotting, co-immunoprecipitation, kinase assays, and proteomics-aware experimental design.
-
HyperFluor™ 594 in Atherosclerosis Assays
2026-09-04
Discover how a goat anti-rabbit IgG secondary antibody can translate atherosclerosis gene evidence into spatially resolved fluorescence data. This article connects ISG20 validation, spectral assay design, and application-specific controls for more defensible immunological measurements.
-
Sulfaphenazole Optimization for Safer Anti-TB Leads
2026-09-04
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP 2C9 inhibition, a liability associated with potential drug–drug interactions. Compound 10d emerged as the clearest lead, combining a reported MIC of 5.69 μg/mL with CYP 2C9 inhibition above 10 μM and low cytotoxicity.
-
AmpliFold Capture-and-Release for LFA Sensitivity
2026-09-03
The ChemRxiv study introduces AmpliFold, a capture-and-release architecture that temporarily sequesters HER2-containing complexes before triggered release and high-affinity rebinding. By expanding the effective capture area and optimizing cleavable Fab conjugates, the approach improved lateral flow assay sensitivity while addressing kinetic limitations associated with low receptor densities and large nanoparticles.
-
BV6 IAP Antagonist: Cell-Death Workflow
2026-09-03
BV6 provides a practical way to probe IAP-dependent survival, apoptosis induction, and radiosensitization in cancer models. This workflow connects concentration-response testing with lysosomal membrane and cathepsin assays, helping researchers distinguish pathway activation from terminal cell damage.
-
Romidepsin (FK228) Workflow for HDAC Research
2026-09-02
Romidepsin (FK228) enables controlled studies of class I HDAC inhibition, chromatin remodeling, cell cycle arrest, and apoptosis. This practical guide connects dose–response experiments with proteomic target-mapping strategies inspired by recent NSCLC research, while emphasizing formulation, timing, and interpretation controls.
-
DMH1 as a Selective ALK2 Inhibitor
2026-09-02
DMH1 provides a focused way to perturb BMP–ALK2 signaling in intestinal organoids and non-small cell lung cancer models. This guide connects pathway readouts with practical dosing, formulation, migration, and differentiation workflows while separating established product findings from assay recommendations.